TW200635612A - Use of cyanine dyes for the diagnosis of proliferative diseases - Google Patents

Use of cyanine dyes for the diagnosis of proliferative diseases

Info

Publication number
TW200635612A
TW200635612A TW095100548A TW95100548A TW200635612A TW 200635612 A TW200635612 A TW 200635612A TW 095100548 A TW095100548 A TW 095100548A TW 95100548 A TW95100548 A TW 95100548A TW 200635612 A TW200635612 A TW 200635612A
Authority
TW
Taiwan
Prior art keywords
diagnosis
proliferative diseases
cyanine dyes
administration
less
Prior art date
Application number
TW095100548A
Other languages
English (en)
Inventor
Kai Licha
Michael Schirner
Martin Pessel
Malte Bahner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200635612(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of TW200635612A publication Critical patent/TW200635612A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW095100548A 2005-01-07 2006-01-06 Use of cyanine dyes for the diagnosis of proliferative diseases TW200635612A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05000276A EP1679082A1 (en) 2005-01-07 2005-01-07 Use of cyanine dyes for the diagnosis of proliferative diseases

Publications (1)

Publication Number Publication Date
TW200635612A true TW200635612A (en) 2006-10-16

Family

ID=34933224

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095100548A TW200635612A (en) 2005-01-07 2006-01-06 Use of cyanine dyes for the diagnosis of proliferative diseases

Country Status (23)

Country Link
EP (2) EP1679082A1 (zh)
JP (1) JP5578765B2 (zh)
KR (1) KR20070092270A (zh)
CN (1) CN101128218A (zh)
AR (1) AR052190A1 (zh)
AU (1) AU2006204496A1 (zh)
BR (1) BRPI0606411A2 (zh)
CA (1) CA2594390C (zh)
CR (1) CR9232A (zh)
DO (1) DOP2006000005A (zh)
GT (1) GT200600001A (zh)
IL (1) IL182499A0 (zh)
MX (1) MX2007008300A (zh)
NO (1) NO20074036L (zh)
NZ (1) NZ554917A (zh)
PA (1) PA8659101A1 (zh)
PE (2) PE20100449A1 (zh)
RU (1) RU2007129919A (zh)
TW (1) TW200635612A (zh)
UA (1) UA89976C2 (zh)
UY (1) UY29323A1 (zh)
WO (1) WO2006072580A1 (zh)
ZA (1) ZA200706533B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816475A1 (en) * 2004-07-22 2007-08-08 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
EP1745739A3 (en) * 2005-07-14 2009-04-22 Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Präs. d. Phys.-Techn. Bundesanstalt Optical imaging of rheumatoid arthritis
CA2681790A1 (en) * 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
WO2009152440A1 (en) * 2008-06-13 2009-12-17 Cedars-Sinai Medical Center Small molecule ligand-drug conjugates for targeted cancer therapy
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
EP2451487A1 (en) 2009-07-09 2012-05-16 F. Hoffmann-La Roche AG In vivi tumor vasculature imaging
SG177763A1 (en) 2009-07-28 2012-03-29 Hoffmann La Roche Non-invasive in vivo optical imaging method
JP2011046662A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
JP2011046663A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
US8401618B2 (en) 2009-08-28 2013-03-19 Visen Medical, Inc. Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique
US8401619B2 (en) 2009-09-22 2013-03-19 Visen Medical, Inc. Systems and methods for virtual index-matching of diffusive media
BR112012028006A2 (pt) 2010-05-07 2016-08-02 Hoffmann La Roche método de imuno-histoquímica (ihq), uso de um domínio de ligação, kit e domínio de ligação terapeuticamente ativo
JP6100704B2 (ja) 2011-03-07 2017-03-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 治療用抗体についてのインビボ試験の手段および方法
EP2683413A1 (en) 2011-03-07 2014-01-15 F.Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
KR101373108B1 (ko) 2012-01-20 2014-03-27 이화여자대학교 산학협력단 폴리메틴 체인에 메조-반응작용기를 갖는 신규한 시아닌 유도체 및 이의 제조방법
CN102608051B (zh) * 2012-02-21 2015-04-08 中国科学院化学研究所 用于诊断白血病的试剂盒
CN102703569B (zh) * 2012-05-24 2014-04-09 中国科学院化学研究所 菁染料的新用途
CN102706787B (zh) * 2012-05-24 2015-04-08 中国科学院化学研究所 菁染料的新用途
US10743768B2 (en) 2012-10-15 2020-08-18 Visen Medical, Inc. Systems, methods, and apparatus for imaging of diffuse media featuring cross-modality weighting of fluorescent and bioluminescent sources
WO2014065439A1 (en) * 2012-10-26 2014-05-01 Canon Kabushiki Kaisha Cancer cell inhibitory drug and cancer stem-cell detection probe
US20150367004A1 (en) * 2012-12-10 2015-12-24 Molecular Targeting Technologies, Inc. Compositions and methods of diagnosing ocular diseases
CA2935690A1 (en) 2013-12-31 2015-07-09 Memorial Sloan Kettering Cancer Center Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real-time
RU2565645C1 (ru) * 2014-09-05 2015-10-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ рентгендиагностики глубины инвазии рецидива рака вульвы в мягкие ткани
CA2970719C (en) 2014-12-15 2023-08-01 Memorial Sloan Kettering Cancer Center Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging
AU2016374246A1 (en) 2015-12-15 2018-06-28 Cornell University Imaging systems and methods for tissue differentiation, e.g., for intraoperative visualization
AU2017368005A1 (en) 2016-11-30 2019-06-20 Cornell University Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
CA3095410A1 (en) 2018-03-30 2019-10-03 Perkinelmer Health Sciences, Inc. Systems and methods for 3d reconstruction of anatomical organs and inclusions using short-wave infrared (swir) projection tomography
EP4015004A1 (en) 2020-12-18 2022-06-22 Phi Pharma SA Proteoglycan specific branched peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
JP2006513293A (ja) * 2003-01-24 2006-04-20 シエーリング アクチエンゲゼルシャフト 親水性チオール−反応性シアニン色素及び蛍光診断のための生物分子との接合体
EP1816475A1 (en) * 2004-07-22 2007-08-08 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases

Also Published As

Publication number Publication date
PE20100449A1 (es) 2010-07-25
CN101128218A (zh) 2008-02-20
UY29323A1 (es) 2006-10-02
IL182499A0 (en) 2007-09-20
PE20060872A1 (es) 2006-10-01
JP5578765B2 (ja) 2014-08-27
WO2006072580A1 (en) 2006-07-13
NZ554917A (en) 2010-01-29
NO20074036L (no) 2007-08-03
AU2006204496A1 (en) 2006-07-13
MX2007008300A (es) 2007-09-07
ZA200706533B (en) 2009-07-29
KR20070092270A (ko) 2007-09-12
CA2594390A1 (en) 2006-07-13
AR052190A1 (es) 2007-03-07
RU2007129919A (ru) 2009-02-20
BRPI0606411A2 (pt) 2009-06-23
DOP2006000005A (es) 2006-07-15
CR9232A (es) 2007-11-23
GT200600001A (es) 2006-08-22
EP1679082A1 (en) 2006-07-12
EP1833513A1 (en) 2007-09-19
PA8659101A1 (es) 2006-09-08
JP2008526802A (ja) 2008-07-24
UA89976C2 (ru) 2010-03-25
EP1833513B1 (en) 2013-03-06
CA2594390C (en) 2013-10-22

Similar Documents

Publication Publication Date Title
TW200635612A (en) Use of cyanine dyes for the diagnosis of proliferative diseases
TW200716552A (en) Novel thiophene derivatives
MY147949A (en) Hydrogenated benzo[c]thiophene derivatives as immunomodulators
EP1732602A4 (en) CYTOTOXIC MEDIATION OF CELLS WITH SUPERFICIAL EXPRESSION OF MCSP
EP1906968A4 (en) NEW SCHEMES FOR ORAL MONOPHASIC CONTRAZEPTIVA
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
PL2026803T3 (pl) Kompozycje R(+) i S(-) pramipeksolu i sposoby ich zastosowania
TW200731987A (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
WO2011053901A3 (en) Magnetic nanostructures as theranostic agents
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
SI1727817T1 (sl) Azabiciklooktan-3-onski derivati in njihova uporaba
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
TW200637875A (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
PT2185561E (pt) Derivados de 1,2,3,4-tetra-hidropirrolo(1,2-a)pirazina-6- carboxamidas e de 2,3,4,5-tetra-hidropirrolo(1,2-a)-diazepina-7- carboxamidas, sua preparação e sua aplicação em terapia
HK1086493A1 (en) Treatment of proliferative diseases with epothilone derivatives and radiation
MY139010A (en) 6-azo-5, 5'-dihydroxy -7,7'-disulfo-2-2'-dinaphthylamine derivatives
TW200610526A (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
WO2007121883A3 (de) 1,4:3,6-dianhydromannitol-derivate und deren verwendung
TW200744645A (en) Contrast agents for myocardium perfusion imaging
RU2005111872A (ru) Антитромботическое, антикоагулянтное, фибриндеполимеризационное, фибринолитическое средство
WO2004089409A3 (de) Mittel für die photodynamische diagnostik und therapie von bösartigen tumoren
RU2004128095A (ru) 2-амино-7-бром-4-ацетилтиазоло[5,4-b]индола, защищающий организм от гипобарической и гемической гипоксии и печень от отравления четыреххлористым углеродом